Št. zadetkov: 11
Doktorska disertacija
Oznake:
Evropeizacija;Varstvo manjšin;Državljanstvo;Doktorske disertacije;
Poglobljena evropeizacija skozi zunanje upravljanje Evropske unije
Leto:
2018
Vir:
Fakulteta za družbene vede (UL FDV)
Izvirni znanstveni članek
Oznake:
barriers;co-creation;drivers;professionals;Slovenia;
The academic contribution to the field is twofold. Firstly, the paper identifies co-creation drivers and barriers from the professionals’ point of view ‒ a largely overlooked perspective in the relevant literature. Secondly, by being placed in the Slovenian administrative context, the paper compleme ...
Leto:
2022
Vir:
Fakulteta za upravo (UL FU)
Izvirni znanstveni članek
Oznake:
public services;public service improvement;co-creation;drivers;barriers;decision support model;
Purpose This paper aims to develop a model that supports public organisations in making informed strategic decisions as to which public services are most suitable to be improved through co-creation. Thus, it first identifies the features that make public services (un)suitable for co-creation and the ...
Leto:
2024
Vir:
Fakulteta za upravo (UL FU)
Diplomsko delo
Oznake:
sintezni analogi klatrodina;Agelas clathrodes;humane celice;tekočinska citometrija;
Vrednotenje proaptotičnega delovanja sinteznih analogov klatrodina na humanih celicah embrionalnega karcinoma NTERA-2 klon D1
Leto:
2014
Vir:
Fakulteta za farmacijo (UL FFA)
Pregledni znanstveni članek
Oznake:
ligandi;imunoterapevtiki;NOD1 agonisti;NOD1 antagonisti;NOD2 agonisti;NOD2 antagonisti;adjuvants;cancer immunotherapy;immunotherapeutics;NOD1agonists;NOD1 antagonists;NOD2 agonists;NOD2 antagonists;
In the last decade, cancer immunotherapy has emerged as an effective alternative to traditional therapies such as chemotherapy and radiation. In contrast to the latter, cancer immunotherapy has the potential to distinguish between cancer and healthy cells, and thus to avoid severe and intolerable si ...
Leto:
2019
Vir:
Fakulteta za farmacijo (UL FFA)
Doktorska disertacija
Oznake:
receptor EP4;prostaglandinski receptorji;receptor NOD2;modelna celična linija MEC-1;protitumorno delovanje;terapija bolnikov;
Kronična limfocitna levkemija (KLL) je najbolj pogosta podvrsta levkemije v zahodnem svetu, pri kateri pride do kopičenja malignih, nefunkcionalnih limfocitov B v periferni krvi. KLL je sprva počasi napredujoča bolezen, ki ima zelo heterogen klinični potek. Veliko bolnikov ob postavitvi diagnoze nim ...
Leto:
2021
Vir:
Fakulteta za farmacijo (UL FFA)
Izvirni znanstveni članek
Oznake:
co-creation;drivers;barriers;decision support model;organizational maturity;
The paper conceptualizes a multi-attribute decision support model for the assessment of organizational maturity for co-creation, specifically for public organizations. This is achieved on the basis of a systematic literature re-view (i.e. content analysis) and analysis of two European case studies o ...
Leto:
2022
Vir:
Fakulteta za upravo (UL FU)
Izvirni znanstveni članek
Oznake:
collaborative innovation;co-creation;co-production;content analysis;Web of Science;
This paper presents the results of the content analysis of 139 Web of Science papers focused on collaborative innovation with external stakeholders of public administration, specifically on co-production and co-creation. The analysis included papers published between 2009 and 2018 and was based on a ...
Leto:
2019
Vir:
Fakulteta za upravo (UL FU)
Izvirni znanstveni članek
Oznake:
B-cell leukemia and lymphoma;chronic lymphocytic leukemia;prostaglandin EP4 receptor;selective EP4 receptor agonist;monoclonal antibodies;synergistic effects;
Anti-CD20 monoclonal antibodies (MAbs) have revolutionized the treatment of B-cell leukemia and lymphoma. However, many patients do not respond to such treatment due to either deficiency of the complementary immune response or resistance to apoptosis. Other currently available treatments are often i ...
Leto:
2022
Vir:
Fakulteta za farmacijo (UL FFA)
Izvirni znanstveni članek
Oznake:
chronic lymphocytic leukemia;L-902688;NF-{kappa]B inhibition;prostaglandin E4;receptor;synergistic cytotoxic activity;
Treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL) has significantly improved more recently with the approval of several new agents, including ibrutinib, idelalisib, and venetoclax. Despite the outstanding efficacies observed with these agents, these treatments are ...
Leto:
2021
Vir:
Fakulteta za farmacijo (UL FFA)